Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis.
Rompoti N, Stefanaki I, Panagakis P, Papoutsaki M, Politou M, Vavouli C, Befon A, Kousta F, Lazou E, Zaimi M, Koumprentziotis IA, Chasapi V, Rigopoulos D, Stratigos A, Nicolaidou E.
Rompoti N, et al. Among authors: vavouli c.
J Eur Acad Dermatol Venereol. 2024 Mar 20. doi: 10.1111/jdv.19956. Online ahead of print.
J Eur Acad Dermatol Venereol. 2024.
PMID: 38506605
No abstract available.